Abiopharma

🔍 Schuetz Thomas J. (Director)

Company: Compass Therapeutics, Inc. (CMPX)

Report Date: 2026-01-09

Detailed Transactions and Holdings:

• Sold 46,777 shares of Common Stock at $5.35 per share (Direct)
  Date: 2026-01-09 | Code: F | equity_swap_involved: 0 | shares_owned_after: 6,640,023.00 | transaction_form_type: 4 | Footnotes: F1, F2

Footnotes:

• F1: Represents the number of shares withheld by the Issuer to cover tax withholding obligations in connection with the vesting of restricted stock units ("RSUs").
• F2: 250,000 of the shares represent unvested restricted stock units ("RSU") granted on February 8, 2023. Each RSU represents a contingent right to receive one share of common stock. The award is subject to service-based vesting conditions and vests in four equal annual installments, with the first installment vested on February 8, 2024. 318,750 of the shares represent unvested restricted stock units ("RSU") granted on January 9, 2024. Each RSU represents a contingent right to receive one share of common stock. The award is subject to service-based vesting conditions and vests in four equal annual installments, with the first installment vested on January 9, 2025. 250,000 of the shares represent unvested restricted stock units ("RSU") granted on January 2, 2026. Each RSU represents a contingent right to receive one share of common stock. The award is subject to service-based vesting conditions and vests in four equal annual installments, with the first installment vested on January 2, 2027.